We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug‐induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis.
- Authors
Bihan, Kevin; Weiss, Nicolas; Théophile, Hélène; Funck‐Brentano, Christian; Lebrun‐Vignes, Bénédicte
- Abstract
Aims: Drug‐induced aseptic meningitis (DIAM) is an adverse drug reaction of exclusion; only few studies have addressed this iatrogenic disease. The aim was to characterize DIAM and to identify suspected drugs. Methods: Data were collected from the analysis of the French Pharmacovigilance Database from inception (1 January 1985) to 8 March 2017. All cases were initially analysed according to the French imputability method by institutional pharmacologists (clinicians or pharmacists). Further analyses of well documented cases were then performed. Results: In this study, 329 cases of aseptic meningitis were retrieved from the French Pharmacovigilance Database for a total of 429 suspected drugs. Analysis of 203 well documented cases, including 282 drugs, showed that the main reported classes were intravenous polyvalent immunoglobulin, nonsteroidal anti‐inflammatory drugs (NSAIDs), vaccines, antimicrobials, intrathecal antimetabolites, corticosteroids and antalgics/anaesthetics (except NSAIDs). Lymphocytic (33.0%) and purulent (44.8%) meningitis represented the majority of cases of aseptic meningitis. In other cases, the cerebrospinal fluid was mixed (45–55% of neutrophils +45–55% of lymphocytes) or data about cerebrospinal fluid composition were lacking. Most DIAM cases (96%) had a favourable reported outcome with full recovery or minimal residual symptoms. Conclusion: The most frequently involved drugs in DIAM were intravenous polyvalent immunoglobulin, NSAIDs, vaccines, and antimicrobials and this without being able to differentiate them in terms of biological characteristics. Although further studies are needed to better understand the pathophysiological mechanisms of DIAM, a continuous enrichment of pharmacovigilance databases is essential to identify new signals and to help clinicians in the understanding of DIAM.
- Subjects
PHARMACOEPIDEMIOLOGY; MENINGITIS; DRUG side effects; IATROGENIC diseases; CEREBROSPINAL fluid; INTRAVENOUS anesthetics; ANTI-inflammatory agents; ANTIMETABOLITES
- Publication
British Journal of Clinical Pharmacology, 2019, Vol 85, Issue 11, p2540
- ISSN
0306-5251
- Publication type
Article
- DOI
10.1111/bcp.14073